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A systematic review of associations between common SNCA
variants and clinical heterogeneity in Parkinson’s disease
Camilla Christina Pedersen1,2, Johannes Lange 1,2, Marthe Gurine Gunnarsdatter Førland1, Angus D. Macleod 3, Guido Alves1,2,4 and
Jodi Maple-Grødem 1,2✉
There is great heterogeneity in both the clinical presentation and rate of disease progression among patients with Parkinson’s
disease (PD). This can pose prognostic difficulties in a clinical setting, and a greater understanding of the risk factors that contribute
to modify disease course is of clear importance for optimizing patient care and clinical trial design. Genetic variants in SNCA are an
established risk factor for PD and are candidates to modify disease presentation and progression. This systematic review aimed to
summarize all available primary research reporting the association of SNCA polymorphisms with features of PD. We systematically
searched PubMed and Web of Science, from inception to 1 June 2020, for studies evaluating the association of common SNCA
variants with age at onset (AAO) or any clinical feature attributed to PD in patients with idiopathic PD. Fifty-eight studies were
included in the review that investigated the association between SNCA polymorphisms and a broad range of outcomes, including
motor and cognitive impairment, sleep disorders, mental health, hyposmia, or AAO. The most reproducible findings were with the
REP1 polymorphism or rs356219 and an earlier AAO, but no clear associations were identified with an SNCA polymorphism and any
individual clinical outcome. The results of this comprehensive summary suggest that, while there is evidence that genetic variance
in the SNCA region may have a small impact on clinical outcomes in PD, the mechanisms underlying the association of SNCA
polymorphisms with PD risk may not be a major factor driving clinical heterogeneity in PD.
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INTRODUCTION
There is great heterogeneity in both the clinical presentation
and the rate of disease progression between patients with
Parkinson’s disease (PD)1,2. While PD is characterized by motor
symptoms such as resting tremor, bradykinesia, rigidity, and
postural instability, patients also experience a variety of non-
motor symptoms, including cognitive impairment and demen-
tia, sleep disorders, depression, anxiety, hallucinations, and
hyposmia3. These non-motor symptoms complicate the clinical
management of the disorder and are significant determinants of
poor quality of life for patients and their caregivers. The
observed heterogeneity can also pose prognostic difficulties in
a clinical setting, and a greater understanding of the risk factors
that contribute to modify disease course is of importance in
terms of informing patients more accurately how they may be
affected by the disease and developing personalized medicine
strategies for patient management. Further, there is increased
interest in targeting patients with a higher risk of specific
disease outcomes in tailored clinical trials.
A logical first step in seeking genetic modifiers for progression in
PD is to examine well-established PD susceptibility genes. These
include SNCA, the gene encoding the α-synuclein protein that
constitutes the major protein component of Lewy bodies (LBs)4.
The abnormal aggregation of α-synuclein has a primary role in the
formation of the LBs and other α-synuclein pathological aggre-
gates and is regarded as a critical step in the molecular
pathogenesis of PD5. In familial cases of PD, specific mutations or
copy number variations (CNVs) of SNCA have been shown to cause
increased production of α-synuclein and this is correlated with
increasing disease severity6,7. Such mutations and CNVs of SNCA
are rare in the general PD population, but candidate gene studies
and genome-wide association studies (GWAS) have established the
SNCA locus as a risk factor for idiopathic PD8,9 and accordingly as a
promising candidate for disease modification.
The analysis of common polymorphisms in the SNCA region
with clinical outcomes or age at PD onset has received much
attention, but the use of different clinical scales, populations,
and study designs complicates the comparison of the results,
and no clear disease-modifying polymorphisms have been
identified so far. For a better understanding of the impact of
SNCA genetic polymorphisms on the progression of disease, a
comprehensive overview of the associations between clinical
evaluations and SNCA genotypes in PD is necessary. This
systematic review aims to summarize and compare all available
primary literature that has evaluated the association between
SNCA polymorphisms and any PD clinical outcome. The review is
limited to the analysis of patients with idiopathic PD, but given
the broad symptomatology accredited to PD, no restrictions
were placed on the clinical outcome measures evaluated in the
studies. The potential contribution of SNCA polymorphisms to
the clinical manifestations of PD is summarized. Further, the
implications of the results for our understanding on the
pathophysiology of PD and the design of future studies are
discussed.
RESULTS
Characteristics of included studies
The search strategy yielded 597 unique studies (Fig. 1) of which 58
were found to be eligible for inclusion. Of the 58 studies included
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in the review, 24 evaluated PD age at onset (AAO; median size
832, range 81–28,568 participants) and 41 evaluated clinical
features of PD (median size 330, range 50–2011 participants), and
predominantly included patients of European (Europe, Australia,
or North America; n= 37) or Asian ancestry (n= 24). Only one
study population was from South America (Brazil). All studies used
defined diagnostic criteria for the diagnosis of PD (Table 1) as
specified in the inclusion criteria for the review, though notably
one study additionally incorporated data from a commercial
genotyping project (23andMe) in which the diagnosis of PD was
self-reported10. Assessment of bias in each study revealed that
those that stood out as having the lowest number of sources of
potential bias replicated the findings in independent cohorts,
properly accounted for multiple testing, or were based on
population-based cohorts (Supplementary Table 1).
A total of 51 different SNCA genetic polymorphisms were
investigated, comprising 50 single-nucleotide polymorphisms
(SNPs) and variations in the complex microsatellite D4S3481
known as REP1, located approximately 10 kb upstream of the
translational start of SNCA. The location and population
frequency (European and East Asian) of each polymorphism is
provided (Supplementary Table 2). Of the 51 polymorphisms
studied, 6 were reported to be significantly associated with AAO
and 10 were reported to be significantly associated with a
clinical outcome (Fig. 2 and Supplementary Table 3), defined by
a p value of <0.05, unless the authors of the study specifically
reported that the association was not significant after adjust-
ment for multiple testing or covariates. A summary of all of the
SNPs investigated and not shown to be significantly associated
with any clinical outcome analyzed is given in Supplementary
Fig. 1 and Supplementary Table 3.
The association of SNCA polymorphisms with age at PD onset
One of the distinguishing features of autosomal-dominant PD
caused by several SNCA gene mutations or multiplications is an early
AAO, and this has led to an extensive investigation of common SNCA
polymorphisms as modifiers of AAO in idiopathic PD. We identified
24 studies that assessed the role of SNCA polymorphisms on
modifying AAO and 6 out of the 40 studied SNPs were associated
with differences (Fig. 2 and Supplementary Table 3).
Seven small studies, including patients of European (n= 6)11–16
and Asian (n= 2)16,17 ancestry, did not find evidence that the
SNCA REP1-risk genotype impacts AAO in PD (Fig. 2 and
Supplementary Table 3). In contrast, three studies showed a
significant association between REP1 and an earlier AAO18–20.
Further, a meta-analysis on data from 4190 cases from 15 sites
involved in the Genetic Epidemiology of Parkinson’s Disease (GEO-
PD) Consortium, including some of the previously cited studies,
found higher REP1 scores (defined here as the sum of allele score,
with each 259-, 261-, or 263-bp allele contributing 0, 1, or 2 points,
respectively) to be associated with an earlier AAO (hazard ratio
(HR)= 1.06; p= 0.01)21.
Five studies took a broader approach to identify genetic AAO
modifiers by analyzing the association of SNPs across many genes
previously associated with the risk of sporadic PD, including
polymorphisms in the SNCA region10,11,22–24. In a German study of
21 SNPs associated with PD risk, AAO was assessed in 1396
patients with PD and rs356219 from the SNCA region was shown
to significantly contribute to earlier AAO (rs356219-G, p= 0.001)23.
These data are consistent with reports from both a Chinese
population of 685 cases (rs356219-G dominant model, p= 0.02)25
and a Spanish population of 898 cases (rs356219-G log-additive
model, p= 0.0034)24, each of which reported that carriers of the
Fig. 1 Study selection flow diagram. Asterisk (*): eight further articles were retrieved from a manual search of the 50 evaluated papers’
references (n= 5) and from the wider PD literature (n= 3). iPD idiopathic Parkinson’s disease, SNP single-nucleotide polymorphism.
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rs356219-G allele had a significantly younger AAO than carriers of
rs356219-A allele. Notably, the results from the Spanish population
were extended to identify a three-loci epistatic combination of
rs356219 with RPTOR rs11868112 and RPS6KA2 rs6456121 that was
associated with AAO in both the discovery cohort (n= 898; odds
ratio (OR) 2.89; p < 0.0001) and a replication sample from the
International Parkinson Disease Genomics Consortium (IPDGC;
n= 4170; OR 1.56; p= 0.046–0.047). The most recent AAO study
was also the largest study to be identified in this review, achieved
by combining cases from the IPDGC with participants from the
23andMe research data set, which consisted of customers of the
personal genetics company (23andMe, Inc.) who self-reported
diagnosis and their age of PD diagnosis10: Blauwendraat et al. took
two approaches, first performing a GWAS for AAO10. The top SNP
associated with PD AAO in this GWAS was rs356203, resulting in
an earlier AAO by approximately 0.6 years (p_meta= 1.90E−12).
Interestingly, rs356203 has previously been shown to be
associated with an increased risk of PD8 but has not been
investigated for an association with other clinical outcomes in PD.
Second, the authors analyzed an updated set of 44 PD-risk SNPs
and identified variants in six different genes to be significantly
associated with AAO, including the SNCA SNP rs365182 (p=
1.12 × 109)10.
Motor outcomes in PD
PD is primarily a movement disorder and accordingly motor signs
and symptoms were the most frequent clinical outcomes
evaluated. Of the 22 studies analyzing a total of 16 polymorph-
isms, 9 reported a significant association between a motor-related
outcome and 4 SNPs26–31 or the REP1 polymorphism32–34 (Fig. 2
and Supplementary Table 3).
In cross-sectional analyses, significant associations of SNCA
polymorphisms with Unified Parkinson’s Disease Rating Scale
(UPDRS) scores were found in two Asian populations for REP1–263
allele carriers (UPDRS III, β 3.921; p= 0.026)34 and rs11931074
(UPDRS II, standardized coefficient (SC) −0.083; p= 0.035; UPDRS
III, SC −0.140; p ≤ 0.001)28. However, these results were not
replicated by other studies (Fig. 2 and Supplementary Table
3)27,35,36, including a large study from the Chinese National
Fig. 2 Summary of SNCA polymorphisms identified in this review that were reported to be associated with a clinical outcome in
Parkinson’s disease. a Schematic of SNCA showing the location of each polymorphism. Exons are indicated by boxes. Chromosome 4
positions according to GRCh 37. Adapted from the output generated by LDLink83. b The number of studies reporting a significant association
of a clinical outcome with the polymorphism indicated. c The number of studies reporting no significant association between a clinical
outcome with the polymorphism indicated. In both b and c, the analysis of clinical outcomes is separated according to a cross-sectional (cs) or
longitudinal (long) study design. A single study can be recorded more than once if both designs were included in the manuscript or if the
study reported both significant and non-significant associations for a SNP in the same category. Full details of the SNPs and the outcomes in
each category are given in Supplementary Tables 2 and 3. Asterisk (*): the unadjusted p value was <0.05 but the authors reported that the
association did not remain significant after adjustment for multiple testing or covariates. Dagger (†): the study identified the association in a
discovery cohort and replicated the finding in an independent cohort. AAO age at onset, cs cross-sectional, H&Y Hoehn and Yahr, long
longitudinal.
C.C. Pedersen et al.
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Consortium on Neurodegenerative Diseases (CNCPD; n= 2011)36.
Cooper et al. showed an association between rs356182 and
tremor-dominant (TD) vs. postural-instability gait disorder motor
subtypes (corrected p= 0.04), which they subsequently replicated
in an independent multi-center cohort (p= 0.002). In both the
discovery and replication cohorts, the authors found that the
rs356182-GG genotype was associated with a more TD pheno-
type29. Cooper et al. built on these findings and showed that
rs356182 also predicted slower progression of motor impairment,
with the annual rate of increase in UPDRS III scores found to be
approximately 1 point per year less in rs356182-GG carriers
compared to those with the AG or AA genotypes (p= 0.01)29.
Further evidence that SNCA polymorphisms predict the rate of
motor symptom decline in PD was reported in work from the
Parkinson Environment and Genes cohort, a prospective,
population-based study of patients in California, USA. In this
study, the risk of faster decline of motor function (defined by a
change of >5 points per year in UPDRS III score) was increased
fourfold in carriers of the REP1–263 allele (OR 4.03; p= 0.004)32.
Few studies have addressed a possible association between
SNCA polymorphisms and the development of motor complica-
tions related to dopaminergic treatment (Supplementary Table 3)
and replication studies are lacking. The development of motor
fluctuations and levodopa-induced dyskinesias (LIDs) up to 13
years from diagnosis was evaluated in patients from the
prospective population-based Cambridgeshire Parkinson’s Inci-
dence from GP to Neurologist (CamPaIGN) cohort. Carriers of
rs356219-A were at increased risk of developing motor fluctua-
tions compared to the rs356219-GG genotype (adjusted HR 1.902;
p= 0.039), while no difference was observed in the development
of LIDs between the two groups (unadjusted p= 0.907)26. Two
studies assessed wearing off (WO): in an Italian study, carriers of
the REP-263 allele were found to have a higher risk of WO
compared to noncarriers at 10 years from disease onset (65.33%
vs. 53.02%; log-rank test p= 0.028), although this result was not
significant in multivariate Cox regression analysis18. In a separate
Chinese study, rs11931074 was not found to be associated with
WO (p= 0.520) in 724 patients with a comparably short disease
duration (rs11931074-T carriers 4.61 ± 4.42 years; rs11931074-GG
carriers 4.78 ± 3.97 years)28. Given the higher risk of motor
problems with increasing disease duration, additional studies of
more advanced PD will be needed to validate these results.
Measures of global PD severity and disability
The Hoehn and Yahr (H&Y) scale provides an overall assessment of
severity of PD based on clinical features and functional disability
and, since its introduction, has remained the most widely used
scale to describe the general severity of PD. Fourteen studies
including a total of 31 different polymorphisms used the H&Y
scale to measure PD severity (Supplementary Table 3), but the
means by which the scale was used varied widely. For example,
Davis et al. report no significant association between rs356219 or
rs11931074 and the annual change in H&Y stage22, while in other
studies these same SNPs were shown to be significantly
associated with either a longer time to a 0.5-point increase in
H&Y stage (rs356219; HR 0.20; p= 0.005)37 or a longer time to
reach H&Y stage ≥3 (mild-to-moderate disability) (rs11931074; HR
0.43; p= 0.03)31. Similarly, REP1 score was reported to be
associated with a longer time to reach H&Y stage ≥4 (severe
disability) (HR 0.87; p= 0.046)38, while reports on the association
of the REP1 polymorphism with H&Y stage at the time of
examination are conflicting34,36. Shi et al. (CNCPD, n= 2011)
reported no associations with H&Y stage in an exploratory study of
9 genetic variants from 6 different genes that included REP136,
while, in a smaller study (n= 172), Ng et al., found an association
between REP1–263 and H&Y stage at examination (β 0.231;
p= 0.008)34. These studies also vary greatly in the rigor of their
design, but variability in the application of the H&Y scale makes a
direct comparison of the results particularly challenging.
Cognitive impairment and the development of dementia in
PD
Cognitive decline is an important aspect of PD as it brings a
substantial additional burden for the patient, caregivers, and the
healthcare system. In 8 of the 21 studies that assessed the association
between 36 SNCA polymorphisms and cognition, 4 SNPs27,31,35,37,39
and the REP1 polymorphism18,34,38 were shown to be significantly
associated with measures of cognitive impairment or the diagnosis of
dementia (Fig. 2 and Supplementary Table 3). Among these,
rs356219 was the most frequently studied SNP. In the most
comprehensive assessment of cognitive performance and
rs356219, Mata et al. analyzed global cognitive function using the
Montreal Cognitive Assessment (MoCA), and memory; attention and
executive function; language processing; and visuospatial skills in
1079 patients with PD of European descent and found no significant
association between rs356219 and any outcome40. Two small studies
did show a significant association of rs356219 with global cognitive
impairment, with conflicting results: in a Chinese explorative study of
50 patients, the rs356219-G allele was significantly associated with an
18% decreased risk of cognitive decline (p= 0.006), measured by the
time to a 1-point decrease on the MoCA scale37. Conversely, a
Brazilian study of 105 patients found that both rs356219 hetero-
zygotes (rs356219-GA; OR 4.74; p= 0.021) and homozygotes
(rs356219-GG; OR 5.74; p= 0.014) had significantly increased risk of
cognitive impairment as defined by an education-corrected Mini-
Mental State Examination (MMSE) cut-off35. Given Mata’s findings
and the small number of participants and events observed in the
latter two studies, there is currently limited support for a role of
rs356219 in modifying cognitive impairment.
The association of rs356219 and dementia in PD has been
studied in three independent populations. The rs356219-G allele
was found to be associated with an increased risk of PD dementia
(PDD; p= 0.01) in a Chinese population of 291 patients39. In
contrast, studies of two European populations of patients with PD
from the UK (CamPaIGN)41,42 and Spain43 found no link between
rs356219 and the risk or development of dementia. All four studies
used clinical diagnostic criteria for PDD (Supplementary Table 3).
The differences in findings could be due to type I errors or reflect
variance in ethnic backgrounds or study design, such as the
inclusion of incident patients vs. patients from specialist units.
One of the largest studies to explore the impact of SNCA
polymorphisms on cognitive decline analyzed the role of REP1
and 19 additional haplotype-tagging SNPs in 922 PD patients from
the Molecular Epidemiology of Parkinson’s Disease study.
Participants were assessed by telephone interview, either directly
with the cases (Modified Telephone Interview for Cognitive Status)
or via proxy (Alzheimer’s Disease Dementia Screening Interview)38.
The group of patients with higher REP1 scores (linked with highest
risk of PD) were shown to have reduced risk of developing
cognitive impairment (HR 0.81; p= 0.0017)38. However, this
protective effect of REP1 on cognitive decline was not replicated
by an Italian study of 426 PD patients which showed that carriers
of the REP1–263 allele (similarly linked with PD risk) showed
significantly increased risk of dementia compared to carriers of
shorter alleles (HR 3.03; p < 0.001)18 or by a Singapore study which
showed that REP1–263 allele carriers were associated with lower
MMSE scores (β –1.46; p= 0.010)34. While these later results are
more aligned with the predicted effect of REP1 on disease
outcomes, it is difficult to directly compare the results because of
the scales used to asses cognition and the handling of the REP1
genotype are different in all three studies.
C.C. Pedersen et al.
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Other non-motor symptoms in PD
Anxiety and depression are two of the most common mental
health symptoms that affect people with PD. Seven studies from
China (n= 6) and Brazil (n= 1) looked at depression or anxiety
and a total of 11 SNCA polymorphisms (Supplementary Table 3).
Only two studies reported a significant association: first, in a small
(n= 105) Brazilian population, the rs2583988-TT genotype was
found to significantly reduce the risk of depression, defined using
the Beck Depression Inventory (OR 0.21; p= 0.046)35, and second,
a large study in China (n= 1047) found that a REP1 “risk allele” (in
this study defined by the copy number of a CA repeat) was
associated with a decreased risk for the presence of mild-to-
marked depression defined using the Hamilton Rating Scale for
depression (OR 0.54; p= 0.049)44. Neither of these findings has
been replicated.
As PD progresses, many patients will develop psychotic
symptoms, primarily hallucinations, which is considered an
important clinical milestone in the course of PD. However, only
two studies reported the association between SNCA and the
incidence of psychosis in PD (Supplementary Table 3). The first
study found no evidence for an association with the SNCA REP1
alleles and psychotic symptoms measured by item 2 of the UPDRS
part I (“benign hallucinations with insight retained” or worse) in the
multi-center NeuroGenetics Research Consortium45. In the second
study, with patients recruited in Italy, REP1–263 allele carriers were
shown to have a 2.69-fold higher risk of developing visual
hallucinations over the course of disease (p= 0.001) recorded
from retrospective review of clinical records18.
Sleep disorders, including excessive daytime sleepiness and
rapid eye movement (REM) sleep behavior disorder (RBD), usually
increase in frequency over the course of PD. RBD is a parasomnia
strongly linked to synucleinopathies and characterized by the
absence of muscle atonia during REM sleep46. In a study of 325
patients with PD from Norway47, possible RBD (pRBD) was
assessed using the RBD screening questionnaire (history of dream
enactment without polysomnographically confirmed REM sleep
without atonia). pRBD was significantly associated with the SNCA
SNP rs3756063 (OR 1.44; p= 0.018) but not rs356165 or
rs2245801. This result was replicated for rs3756063 in 382 patients
from the Parkinson’s Progression Markers Initiative (PPMI) cohort
with marginal significance (OR 1.35; one-sided p= 0.036)47.
Recently, a large study analyzed the effect of four other SNCA
SNPs, selected for their association with risk of PD or isolated RBD,
in the Norwegian and PPMI cohorts and an additional cohort from
McGill University48. Meta-analysis of the three cohorts identified a
significant association of rs287004 with a reduced incidence of
pRBD in PD (OR= 0.76; p= 0.009)48.
Two of the studies identified in this systematic review49,50
diagnosed RBD using the “gold standard” set by the International
Classification of Sleep Disorder-II criteria51. These studies did not
identify an association of RBD with multiple SNCA genetic
polymorphisms in Chinese49 or Italian50 populations (Supplemen-
tary Table 3), but given their relatively small size (n= 5750 and
15249), as typified by studies of clinically defined RBD using
overnight polysomnography, larger studies will be needed to
characterize the impact of SNCA polymorphisms in formally
diagnosed RBD in PD.
Hyposmia, identified as reduced sensitivity to odor, is a
common non-motor symptom of PD and can antedate the typical
motor symptoms by several years52. However, only three small
studies identified in this review have explored the association of
SNCA polymorphisms with hyposmia, each using the 16-item odor
identification “Sniffin’ Sticks” (SS-16) tool to measure hyposmia in
PD. Of these, 1 Chinese study of 50 patients followed for
30 months suggests that of the six SNPs selected, rs894278-G
(HR 0.47; p= 0.029) and rs356219-G (HR 0.32; p= 0.021) were
associated with slower olfactory impairment37. Another Chinese
study of 218 patients report that the rs11931074-TT genotype
increased the risk of hyposmia more than 3-fold compared with
the GG genotype (crude OR 3.41; p= 0.011) but did not find any
significant associations for rs89427853. The third study (n= 295)
found no associations for SS-16 outcome measures and REP1 in a
population from the Netherlands (Supplementary Table 3)54.
DISCUSSION
In this systematic review, we provide a comprehensive summary
of available data regarding the association of SNCA polymorph-
isms and clinical outcomes or AAO in patients with idiopathic PD.
In total, 58 studies were identified that analyzed not only the
association of 51 different SNCA polymorphisms with a broad
range of outcomes, most commonly addressing AAO or motor
impairment that is the core feature of PD, but also a broad range
of non-motor symptoms, including cognitive impairment, sleep,
mental health, and psychosis. Despite the large number of studies
that have been conducted, the only associations that were
replicated by independent studies were between SNCA poly-
morphisms and AAO, and no robust associations were identified
for any of the clinical outcomes considered. This can not only be
attributed to the lack of consistency in study designs and
methodological shortcomings, but may also indicate that com-
mon SNCA variants are not major drivers of the heterogeneity in
clinical presentation and progression that is observed in PD.
For the majority of polymorphisms (n= 39; 76%) identified in
this review, no significant associations were reported with a
clinical outcome or AAO, although it is notable that 31 of these
SNPs were only included in 1 or 2 studies (Supplementary Fig. 1
and Supplementary Table 3). At the other extreme, the most
frequently analyzed polymorphisms rs356219 and REP1 were each
included in 21 studies. These two polymorphisms were among the
very first genetic polymorphisms studied as modifiers of PD
risk16,55,56 and are common in populations of both European and
Asian ancestry, which may contribute to their popularity. The only
replicated association for both rs356219 and REP1 was with AAO
(rs356219, n= 323–25; REP1, n= 418–21). Clinical outcomes were
included in 17 of the studies analyzing rs356219 and 11 of the
studies analyzing REP1. Multiple significant associations, spanning
the spectrum of the clinical outcomes identified in this review,
were reported for both rs356219 and REP1, but notably none were
replicated in independent populations (Fig. 2 and Supplementary
Table 3). Therefore, the results warrant cautious interpretation. The
possible reasons for the lack of robust associations are
discussed below.
While the inclusion criteria pre-specified idiopathic PD diag-
nosed using defined diagnostic criteria, no limitations were put on
other aspects of the study design, and the review revealed a
striking heterogeneity in the design of the study cohorts, sample
size, and the choice of the SNCA polymorphisms and the outcome
measures, each of which can diminish the capacity to compare the
effects of SNCA variants among the different studies. Most striking
was the large heterogeneity in the outcome measures used to
assess the severity of symptoms and disease progression, with >30
different clinical scales or questionnaires identified in the review,
many of which were assessed only once. Adding to the
heterogeneity, even when studies used the most common PD
rating scales, the way in which these scales were applied varied
greatly. This was not only exemplified in the analysis of H&Y
staging (see “Results”) but was also notable in the application of
the UPDRS and MMSE (see outcomes in Supplementary Table 3).
There were also considerable differences in the demographic and
clinical characteristics of the populations studied. Most were
recruited from hospitals or specialized clinics and very few were
population-based cohorts, which can limit the generalizability of
the results. Further, most cohorts were limited to Caucasian or
C.C. Pedersen et al.
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Asian populations, and ethnic differences can preclude the
generalization of the results in genetic studies.
Increasing evidence suggests that variants in SNCA modify the
risk for developing PD by altering the levels of α-synuclein and
promoting the abnormal aggregation into LBs. In this model, small
changes in α-synuclein expression may, over many decades,
predispose to PD and different SNCA variants can contribute to
this by altering the transcriptional regulation of α-synuclein
expression. Of the polymorphisms identified in this review, the
most compelling evidence for a mechanistic role in α-synuclein
regulation is found for REP1 and rs35621957–60. These common
genetic variants have been correlated with higher α-synuclein
expression in vitro58 or with elevated brain or peripheral levels of
α-synuclein in vivo57,59 and it is a biologically plausible hypothesis
that these same mechanisms could impact the heterogeneity that
is observed in PD. The results of this review support a role for
these variants in modifying AAO; however, we did not find any
strong evidence for a link to disease outcomes. Indeed, some
studies even suggest the opposite findings, with those SNPs
increasing PD risk being linked to fewer or milder symptoms, with
examples found for REP138, rs35621926, rs1193107430,39, and
rs35618229. These observations could reflect the shortage of
well-designed replication studies but may also indicate that SNCA
is an initiator of PD risk but not of the development of specific
symptoms or changes in the rates of disease progression. This
hypothesis is in line with a recent study combining data from 13
longitudinal PD cohorts, which found that a genetic risk score
based on 31 PD-risk SNPs was inversely associated with AAO but
not with a comprehensive battery of clinical outcomes61.
Several limitations must be considered in interpreting the
results presented in this review. Despite the large number of
studies identified, the heterogeneity in study design meant that it
was not possible to compare the effect sizes among the studies or
perform a meta-analysis. Further, we only reported the effects of
multiple testing if the authors themselves included this as part of
their analysis plans, although the assessment of potential sources
of bias served to highlight some studies in which this was a
weakness in the design (Supplementary Table 1). The review
inclusion criteria may have missed some works, especially those
that included negative findings related to SNCA as data not
shown, and this highlights the plausible existence of positive
reporting bias. Finally, the Preferred Reporting Items for Systema-
tic reviews and Meta-Analyses (PRISMA) statement was used as a
guide to ensure a rigorous review process; however, we note that
the protocol for our review was not published before the search
was initiated. The strengths of our review include the broad
inclusion criteria, which captured studies of any clinical outcome
associated with PD and including any SNCA polymorphism.
Furthermore, several aspects of the design of each study were
evaluated using pre-determined criteria in order to provide an
assessment of the sources of bias in the studies.
To clarify the role of genetic variation in the SNCA region in PD
heterogeneity, further studies are required. This review has
highlighted the need for well-designed studies with standardized
cohort designs, optimally recruiting patients early in the disease
and following them prospectively using comprehensive batteries
of clinical scales to measure disease severity and progression.
Further, approaches to harmonize how disease progression is
measured should be prioritized. One explanation for the broad
range of tools used is that we currently lack clinical tools that
assess PD progression in an accurate and meaningful way across
the spectrum of disease stages. A new approach was recently
adopted in a GWAS of cognitive and motor progression in which
multiple assessments were combined in a data-driven principal
components analysis to derive scores for composite, motor, and
cognitive progression62. Alternatively, biomarkers may prove to be
more sensitive measures of disease progression, with less
susceptibility to the effects of subjectivity, medication, and
placebo. Clearly, further efforts to improve phenotypic measures
and define disease progression should be pursued.
There was a notable scarcity of population-based incident cases
representative of the general PD population, which may lead to bias
if the associations between polymorphisms and clinical features
vary by age. The mean age of PD onset of the study cohorts
reported in the studies was 58.8 (±5.3) years and the mean age at
examination was 63.7 (±4.5) years. This is typical of general research
studies, which are generally unrepresentative of the population age
distribution of PD63. Finally, it is plausible that the effect sizes of
SNCA polymorphisms will be small, and therefore large studies are
needed to detect small effect sizes, as was demonstrated by the
AAO GWAS of Blauwendraat et al.10. This can result in a trade-off
between sample size and data quality, but there is an increasing
drive for world-leading PD cohorts to collaborate or for journals to
require the deposition of original data in public databases, and
these initiatives will provide excellent platforms to further probe the
role of SNCA variants in PD progression.
The lack of robust findings casts doubts on the relevance of
SNCA SNPs in modifying disease course in PD and suggests that
the genetics of PD risk and progression are largely separate.
However, methodological aspects may explain some of the
discrepancies in the effects of polymorphisms across the different
studies. Most significant associations identified in this review found
that SNCA polymorphisms had minor effects on the clinical
outcomes and so, even if validated, these findings are not currently
relevant in a clinical setting. However, given that α-synuclein is a
major drug target, they have the potential to be used as a genetic
risk stratification tool to reduce variability in clinical trials, and so
further studies using large, well-designed cohorts are warranted.
METHODS
Systematic review strategy
The review process was conducted according to the PRISMA
statement64. A systematic review of literature was performed to
summarize all available primary research reporting the association
of SNCA polymorphisms with clinical features of PD. The following
inclusion criteria were used: subjects were patients with PD
diagnosed according to defined diagnostic criteria (i.e., UKBB,
Gelb, Bower or other clearly defined criteria that were endorsed by
a movement disorder expert (G.A.)), genetic polymorphisms were
within the SNCA gene region, outcomes were any clinical feature
attributed to PD or AAO, the association of SNCA polymorphisms
with outcomes was assessed statistically, and the source was
primary literature in English. Full exclusion criteria are listed in
Supplementary Table 4.
The searches were performed on June 15, 2020 by the first and last
author using two databases (PubMed and Web of Science) and the
following search terms: Parkinson* AND SNCA AND (variant* OR
polymorphism* OR SNP* OR GWAS OR genome-wide) (Supplemen-
tary Table 5). Five hundred and ninety-seven unique publications
were identified, of which 431 were excluded for clearly not meeting
the inclusion and exclusion criteria based on reading the title and
abstract (Supplementary Fig. 2). The remaining 166 publications were
read in full by the first and last author. Cases of diverging opinion
about an article’s eligibility based on the inclusion/exclusion criteria
were discussed at both stages. Fifty publications were found to be
eligible for this review (Fig. 1). Eight further articles were retrieved
from a manual search of the 50 evaluated papers’ references (n= 5)
and from the wider PD literature (n= 3) (identified in Table 1). For the
final 58 publications, the publication year, country of study, cohort
name or main study site, criteria for diagnosis of PD, number of
patients, AAO, age at examination, disease duration, number of
patients followed longitudinally, length of follow-up, SNCA poly-
morphisms, clinical features analyzed, and result of association
analyses (p value of best model) were retrieved, as available. An
C.C. Pedersen et al.
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overview of the papers included in this review (Table 1) and of the
SNCA polymorphisms and outcomes assessed (Supplementary Tables
2 and 3) are provided. The risk of bias for each study was assessed by
the first and last author using a simple traffic light system to grade
potential sources of bias as low level (green), of some concern
(yellow), or high level (red). A third author (J.L.) resolved cases of
diverging assessment. The factors taken into consideration were
sample representativeness, adequate PD definition, adequate assess-
ment of outcomes, multiple comparisons tests, pre-specified plan, and
replication in an independent cohort (Supplementary Table 1).
Reporting summary
Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
DATA AVAILABILITY
The data that support the findings of this systematic review are provided in the
Supplementary files.
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